What this Trial Is About

Researchers are investigating the role of IL-23 in the disease processes of axial and peripheral Spondyloarthritis (SpA). This multicenter, non-randomized prospective study aims to better understand how patients with SpA respond to anti-IL-23 biologic treatments. The study involves patients attending rheumatology departments at several hospitals in France, divided into two groups: those with axial SpA and those with peripheral SpA or psoriatic arthritis. Participants will undergo blood sampling, with a total of 51 mL collected during the study. For patients with peripheral SpA who require it as part of their standard care, synovial fluid will also be collected through aspiration and used for research purposes. The study focuses on analyzing immune cell populations, gene expression, and cytokine production related to IL-23 signaling in these patients. During the four-year study period, researchers will profile open chromatin regions, transcriptomes, genomes, cytokine expression, and perform single-cell transcriptome analysis. These assessments will help characterize immune cells from blood and synovial fluid, identify IL-23 receptor-expressing cells, and correlate findings with patient genotypes. Participants will be closely monitored throughout, with data collected to understand disease mechanisms and responses to biologic therapy.

The Role of IL-23 in Chronic Inflammatory Disease: Exploring the Cellular and Molecular Targets of IL-23 Signaling in Peripheral and Axial Spondyloarthritis